Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jes Birger Hansen
Observed names:
Hansen, Jes B.,
Hansen, Jes Birger,
J. B. Hansen,
J.B. Hansen,
Jes B Hansen,
Jes B. Hansen,
Jes Hansen
show all 7
Institution:
Daiichi Sankyo (Germany)
Observed institutions:
University of California, Los Angeles,
Daiichi Sankyo (Germany),
Novo Nordisk (Denmark),
Coloplast (Denmark),
Leo Pharma (United States),
Miami VA Healthcare System,
Leo Pharma (Denmark),
Icahn School of Medicine at Mount Sinai
show all 8
OpenAlex ID:
A5035132667
Proliferation and Mitogenic Response to PDGF-BB of Fibroblasts Isolated from Chronic Venous Leg Ulcers is Ulcer-Age Dependent11Presented in part at the Gordon Research Conference on Wound Repair July 2–7 1995 and at an IBC meeting on Fibrosis in Washington, DC, April 18–19 1996.
1999
·
Magnus S. Ågren
, Henrik H. Steenfos
, et al.
·
Journal of Investigative Dermatology
·
175
Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVETM European cohort
2007
·
A. Dornhorst
, H-J Lüddeke
, et al.
·
International Journal of Clinical Practice
·
83
Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVETM study
2008
·
A. Dornhorst
, H.-J. Lüddeke
, et al.
·
International Journal of Clinical Practice
·
71
Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis.
2007
·
Paola Fernandez Vojvodich
, Jes B Hansen
, et al.
·
PubMed
·
46
Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study
2021
·
Marcus Schmitt-Egenolf
, Jonatan Freilich
, et al.
·
Dermatology and Therapy
·
43
PDF
Fasting plasma glucose variability as a marker of nocturnal hypoglycemia in diabetes: Evidence from the PREDICTIVE™ study
2009
·
Leo Niskanen
, Antti Virkamäki
, et al.
·
Diabetes Research and Clinical Practice
·
31
Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)
2020
·
Jean-Philippe Lacour
, Anthony Bewley
, et al.
·
Dermatology and Therapy
·
27
PDF
Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE™ study
2008
·
S. Sreenan
, A. Virkamäki
, et al.
·
International Journal of Clinical Practice
·
25
PDF
Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
2021
·
Jo Lambert
, Jes Birger Hansen
, et al.
·
Dermatology and Therapy
·
17
PDF
PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis
2020
·
Linda Stein Gold
, Jes B. Hansen
, et al.
·
Journal of the American Academy of Dermatology
·
17
PDF
Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE‐2 and AMAGINE‐3
2021
·
K. Reich
, J.B. Hansen
, et al.
·
Journal of the European Academy of Dermatology and Venereology
·
14
PDF
Real-world dose adjustments of biologic treatments in psoriasis and their economic impact: a Swedish national population study
2022
·
Alexander Egeberg
, Jonatan Freilich
, et al.
·
Clinical and Experimental Dermatology
·
12
PDF
Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis
2021
·
Georgios Kokolakis
, Kasper Vadstrup
, et al.
·
Dermatology
·
9
PDF
Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
2021
·
Philip Hampton
, Emma Borg
, et al.
·
Psoriasis Targets and Therapy
·
8
PDF
Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors
2021
·
Georgios Kokolakis
, Kasper Vadstrup
, et al.
·
Dermatology and Therapy
·
8
PDF
Real-World Effectiveness and Safety of Field- and Lesion-Directed Treatments for Actinic Keratosis
2020
·
Jes Hansen
, Thomas Larsson
, et al.
·
Journal of Drugs in Dermatology
·
8
Efficacy of Fixed-combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam for Scalp Plaque Psoriasis: Additional Analysis of a Phase II, Randomized Clinical Study.
2020
·
Dharm S Patel
, Karen A Veverka
, et al.
·
PubMed Central
·
8
Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis
2020
·
Jashin J. Wu
, Jes B. Hansen
, et al.
·
Journal of Medical Economics
·
8
Predictors of achieving HbA1c <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study
2013
·
Paul Valensi
, Joseph Shaban
, et al.
·
Current Medical Research and Opinion
·
8
Effect of Calcipotriene/Betamethasone Dipropionate 0.005%/0.064% Foam on Target Lesions in Plaque Psoriasis: A Post-Hoc Analysis
2020
·
Karen Veverka
, Dharm Patel
, et al.
·
Journal of Drugs in Dermatology
·
2
Calcipotriene Plus Betamethasone Dipropionate Foam for Mild Psoriasis: Pooled Results from Three Randomized Trials
2021
·
Karen Veverka
, Jes Hansen
, et al.
·
Journal of Drugs in Dermatology
·
1
Ad1 Persistence of Biologic Therapies for the Treatment of Plaque Psoriasis - a National Longitudinal Observational Population Study in Sweden
2019
·
N.M. Stelmaszuk-Zadykowicz
, E. Apol
, et al.
·
Value in Health
·
1
PDF
Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial
2026
·
Esther N Olíva
, Francesco Cottone
, et al.
·
The Lancet Haematology
Healthcare resource utilization in patients receiving quizartinib or placebo in combination with chemotherapy for newly diagnosed, FLT3-ITD+ acute myeloid leukemia: An analysis from the QuANTUM-first trial
2025
·
Harry Erba
, Jes Hansen
, et al.
·
Blood
PDF
16127 Efficacy of ingenol mebutate in patients with actinic keratosis on face and scalp: Subgroup analysis of a 12-month observational follow-up study according to age (<65 and ≥65 years)
2020
·
Hee Jin Kim
, Nikeshia Dunkelly-Allen
, et al.
·
Journal of the American Academy of Dermatology
Show more works
View as search
Works count:
39
Citation count:
622
H-index:
12
I10-index:
12
Year
Topic
Type
